Phio Pharmaceuticals Corp. (PHIO) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-8.54 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.91 vs est $-8.54 (beat +89.3%). 2025: actual $-1.45 vs est $-1.57 (beat +7.3%). Analyst accuracy: 0%.
PHIO Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Phio Pharmaceuticals Corp. in the past 3 months
EPS Estimates — PHIO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.91
vs Est –$8.54
▲ 838.5% off
2025
Actual –$1.45
vs Est –$1.57
▲ 7.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — PHIO
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
